Rachael A Evans1, Eric Kaplovitch2, Marla K Beauchamp3, Thomas E Dolmage4, Roger S Goldstein2, Clare L Gillies5, Dina Brooks6, Sunita Mathur6. 1. Department of Respiratory Medicine, Department of Medicine, University of Toronto, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, England. Electronic address: rachael.evans@uhl-tr.nhs.uk. 2. Department of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada. 3. Department of Respiratory Medicine, Department of Physical Therapy, Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Cambridge, MA. 4. Department of Respiratory Medicine, West Park Healthcare Centre, Toronto, ON, Canada. 5. Department of Health Sciences, University of Leicester, Leicester, England. 6. Department of Respiratory Medicine, Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: Although the aerobic profile of the quadriceps muscle is reduced in COPD, there is conflicting evidence regarding whether this leads to reduced quadriceps muscle endurance. We, therefore, performed a systematic review of studies comparing quadriceps endurance in individuals with COPD with that in healthy control subjects. METHODS: Relevant studies were identified by searching six electronic databases (1946-2011). Full-text articles were obtained after two researchers independently reviewed the abstracts. The results were combined in a random effects meta-analysis, and metaregression models were fitted to assess the influence of the type of measurement. RESULTS: Data were extracted from 21 studies involving 728 individuals with COPD and 440 healthy control subjects. Quadriceps endurance was reduced in those with COPD compared with healthy control subjects (standardized mean difference, 1.16 [95% CI, 1.02-1.30]; P < .001) with a 44.5 s (4.5-84.5 s; P = .029) reduction in COPD (large effect size) when measured using a nonvolitional technique. The relationship between quadriceps endurance in those with COPD and control subjects did not differ when comparing nonvolitional and volitional techniques (P = .22) or when high- or low-intensity tasks (P = .44) were undertaken. CONCLUSIONS: Quadriceps endurance is reduced in individuals with COPD compared with healthy control subjects, independent of the type of task performed.
BACKGROUND: Although the aerobic profile of the quadriceps muscle is reduced in COPD, there is conflicting evidence regarding whether this leads to reduced quadriceps muscle endurance. We, therefore, performed a systematic review of studies comparing quadriceps endurance in individuals with COPD with that in healthy control subjects. METHODS: Relevant studies were identified by searching six electronic databases (1946-2011). Full-text articles were obtained after two researchers independently reviewed the abstracts. The results were combined in a random effects meta-analysis, and metaregression models were fitted to assess the influence of the type of measurement. RESULTS: Data were extracted from 21 studies involving 728 individuals with COPD and 440 healthy control subjects. Quadriceps endurance was reduced in those with COPD compared with healthy control subjects (standardized mean difference, 1.16 [95% CI, 1.02-1.30]; P < .001) with a 44.5 s (4.5-84.5 s; P = .029) reduction in COPD (large effect size) when measured using a nonvolitional technique. The relationship between quadriceps endurance in those with COPD and control subjects did not differ when comparing nonvolitional and volitional techniques (P = .22) or when high- or low-intensity tasks (P = .44) were undertaken. CONCLUSIONS: Quadriceps endurance is reduced in individuals with COPD compared with healthy control subjects, independent of the type of task performed.
Authors: Raolat M Abdulai; Tina Jellesmark Jensen; Naimish R Patel; Michael I Polkey; Paul Jansson; Bartolomé R Celli; Stephen I Rennard Journal: Am J Respir Crit Care Med Date: 2018-02-15 Impact factor: 21.405
Authors: Eulogio Pleguezuelos; Cristina Esquinas; Eva Moreno; Lluis Guirao; Javier Ortiz; Joan Garcia-Alsina; Alex Merí; Marc Miravitlles Journal: Lung Date: 2016-01-07 Impact factor: 2.584
Authors: Eulogio Pleguezuelos; Lluis Guirao; Eva Moreno; Beatriz Samitier; Pilar Ortega; Xavier Vila; Manuel V Garnacho-Castaño; María Majó; Laura Ovejero; Marc Miravitlles Journal: Lung Date: 2018-09-21 Impact factor: 2.584
Authors: Samantha S C Kon; Caroline J Jolley; Dinesh Shrikrishna; Hugh E Montgomery; James R A Skipworth; Zudin Puthucheary; John Moxham; Michael I Polkey; William D-C Man; Nicholas S Hopkinson Journal: BMJ Open Respir Res Date: 2017-03-08
Authors: Erik Frykholm; Sarah Gephine; Didier Saey; Arthur Lemson; Peter Klijn; Eline Bij de Vaate; François Maltais; Hieronymus van Hees; André Nyberg Journal: Sci Rep Date: 2021-06-02 Impact factor: 4.379